Abstract
Nitric oxide (NO) plays a critical role in ischemic heart disease and ischemia-reperfusion. There is an increasing body of evidence to support the role of NO in myocardial and vascular protection in disease. The finding that NO might act as a trigger of late ischemic preconditioning (IPC) might lead to the development of novel anti-ischemic therapy. The role of NO signaling in the cardioprotective effects of ACE inhibitors and angiotensin II type 1 receptor(AT(1)) receptor antagonists is an active area of study.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Cardiotonic Agents / therapeutic use*
-
Cardiovascular Diseases / physiopathology*
-
Cardiovascular Diseases / prevention & control*
-
Evidence-Based Medicine
-
Humans
-
Ischemic Preconditioning, Myocardial
-
Nitric Oxide / physiology*
-
Nitric Oxide / therapeutic use*
-
Receptor, Angiotensin, Type 1
-
Receptors, Angiotensin / therapeutic use
Substances
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Cardiotonic Agents
-
Receptor, Angiotensin, Type 1
-
Receptors, Angiotensin
-
Nitric Oxide